Vitamin B6 (not specified).

Pyridoxal kinase, which phosphorylates pyridoxal to the active coenzyme, is a magnesium-dependent enzyme. Without adequate magnesium the conversion step is limited regardless of how much B6 is supplied. This is the reason the two are paired in so many formulas, and it is a genuine cofactor relationship rather than a marketing pairing.

Converting pyridoxine phosphate to pyridoxal 5-phosphate requires pyridoxine 5-phosphate oxidase, which uses flavin mononucleotide derived from riboflavin. Low riboflavin status therefore limits activation of the non-phosphorylated B6 forms. Someone taking pyridoxine hydrochloride without adequate riboflavin has a bottleneck upstream of the coenzyme.

B12 supports remethylation of homocysteine back to methionine, while PLP supports the transsulfuration route through cystathionine beta-synthase. They handle opposite exits from the same intermediate, so supplying one without the other leaves a route unsupported. Homocysteine is a measured marker, and lowering it is not the same as changing a clinical outcome.

Serine hydroxymethyltransferase, which loads a one-carbon unit onto tetrahydrofolate from serine, is PLP-dependent. B6 status therefore governs how well the folate cycle is supplied with one-carbon units. The two are inseparable in practice, which is why B-complex products carry both.

The kynurenine pathway that converts tryptophan toward niacin depends on PLP at more than one step. When B6 is low the pathway backs up and xanthurenic acid rises in urine, which is the basis of the classic tryptophan load test. This is a well-characterised biochemical readout, not a symptom measure.

The decarboxylation of 5-hydroxytryptophan to serotonin requires PLP as coenzyme. Supplying the precursor without adequate B6 leaves the conversion step under-supported. The pairing is standard formulation practice and rests on the enzymology rather than on combination trials.

PLP is the coenzyme for glutamate decarboxylase, the single enzyme that produces GABA in the nervous system. This is one of the clearest B6 dependencies in neurochemistry. Note that oral GABA itself crosses the blood brain barrier poorly, so the relevance here is to endogenous synthesis rather than to a supplement pairing.

Methionine is catabolised through homocysteine to cystathionine and then cysteine, and both of those steps need PLP. Higher methionine intake therefore raises the demand for B6. This is a genuine load-dependent relationship rather than a fixed ratio.

Zinc and PLP both participate in amino acid metabolism and are jointly depleted in poor overall intake. They are co-formulated on that basis. The relationship is co-dependence within shared pathways rather than one enabling the other directly.

Delta-aminolevulinic acid synthase condenses glycine with succinyl-CoA using PLP as coenzyme, which is the committed step of heme production. Iron is incorporated at the end of the same pathway. Adequate iron with inadequate B6 leaves the pathway short at the start.

Glycine is the amino acid substrate for the PLP-dependent first step of heme synthesis, and its breakdown through the glycine cleavage system is also PLP-dependent. B6 status therefore sits on both the use and the disposal side of glycine handling.

Cysteine is generated from homocysteine and serine through two consecutive PLP-dependent enzymes. Low B6 restricts endogenous cysteine supply, which in turn constrains glutathione synthesis. Supplying cysteine directly bypasses that dependence.

B6 status affects glutathione indirectly by governing how much cysteine the transsulfuration pathway can deliver, since cysteine is the rate-limiting amino acid for glutathione synthesis. The link is two steps removed, so it is mechanistic rather than something you would expect to see as a direct dose response.

Both deliver B6 activity but by different routes, and stacking an unspecified B6 product with a P5P product is how people unknowingly exceed intended totals. B6 is the one water-soluble vitamin with a well-established upper limit tied to sensory nerve effects at sustained high intakes. Adding the two together without counting both is the practical risk.

Tyrosine is converted to L-DOPA and then decarboxylated to dopamine by a PLP-dependent enzyme. B6 supports the second step, not the first, which is the rate-limiting one. That distinction matters: adequate B6 permits the pathway but does not drive it.

Alanine glyoxylate aminotransferase, which diverts glyoxylate away from oxalate, is PLP-dependent, so B6 status influences how much oxalate the body makes. Calcium in the gut binds dietary oxalate and limits its absorption. The two act on different sources of the same compound, which is why they show up together in stone-risk discussions.

Pyridoxine 5-phosphate oxidase requires FMN, so riboflavin status gates the final activation of B6 to its coenzyme form. Anyone using a plain pyridoxine product depends on this step. It is one of the strongest arguments for taking B vitamins as a group rather than singly.

The body makes a portion of its niacin from tryptophan, and kynureninase in that route needs PLP. Poor B6 status therefore lowers the endogenous contribution and raises reliance on dietary niacin. The conversion is inefficient at baseline, roughly 60 to 1 by mass, so this is a supporting route rather than a main supply.

Thiamine and B6 sit in adjacent metabolic territory and are depleted by overlapping causes, including heavy alcohol intake. B-complex products carry them together for that reason. The pairing is convention supported by shared depletion patterns rather than a direct enzymatic dependency.

Serine donates a one-carbon unit to folate and condenses with homocysteine to form cystathionine, and PLP is the coenzyme for both reactions. Serine availability and B6 status therefore constrain the same two exits. This is a substrate and coenzyme relationship, not an additive effect.